ReviewOxidative medicine and cellular longevity2018
Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1.
Review in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 3 syntheses or guidelines pooled it, 384 citations in OpenAlex.
- Sirtuins in intervertebral disc degeneration: current understanding.Molecular medicine (Cambridge, Mass.) · 2024Pooled it
- Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2023Pooled it
- Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer's disease: A systematic review.Frontiers in aging neuroscience · 2022Pooled it
- Resveratrol Ameliorates Brain Functions During Gestation in Mancozeb-Low-Dose-Induced Brain Disorders via Mitigating Inflammation, Lipid Peroxidation, Mitochondrial Dysfunction, DNA Damage, Cell Death, and Histopathological Alterations.Molecular neurobiology · 2026Article
- Resveratrol and neuroprotection: modulation of cellular dynamics and signaling networks in neurodegenerative diseases.Inflammopharmacology · 2026Review
- FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential.Redox biology · 2026Review
- Resveratrol as a potential natural compound to ameliorate cognitive impairment in aluminum-exposed mice: impacts on behavior, purinergic system, and brain inflammation.Metabolic brain disease · 2026Article
- Potential Protection Against Parkinson's Disease by Ergothioneine-Nature's Multifactorial Neuroprotectant.Antioxidants (Basel, Switzerland) · 2026Review
- Cell type-specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease.Genome research · 2026Article
- TFEB, FOXO3 and TLR4 in resveratrol-induced autophagy in a mucopolysaccharidosis IIIB mouse model.Experimental & molecular medicine · 2026Article
- Review
- Bioactive Components ofAntioxidants (Basel, Switzerland) · 2026Review
- The Multidirectional Biological Activity of Resveratrol: Molecular Mechanisms, Systemic Effects and Therapeutic Potential-A Review.Nutrients · 2026Review
- LncRNA SNHG1 Knockdown Ameliorates HIV-1 gp120V3 Loop-Induced Microglial Neuroinflammation by Regulating the Autophagy Process.Inflammation · 2026Article
- A Mini-review on Unlocking Cognitive Enhancement: An Innovative Strategy for Optimal Brain Functions.Central nervous system agents in medicinal chemistry · 2026Review
- Nutritional timing and stress biology: intermittent fasting as a hormetic signal for adaptation.Frontiers in nutrition · 2026Review
- Redox-exercise crosstalk in neurodegenerative diseases: mechanistic perspectives on antioxidant interactions with Nrf2-BDNF signaling, autophagy, and mitochondrial plasticity.Frontiers in nutrition · 2026Review
- Resveratrol Supplementation Modulates Endothelial Dysfunction in Alzheimer's Disease (AD):Current neuropharmacology · 2026Article
- Stage-Dependent Function of Astrocytes in Alzheimer's Disease: A Review.Neuroscience insights · 2026Review
- Bidirectional communication between spinal cord injury and gut microbiota, from the bench to the bedside.Frontiers in immunology · 2026Review
145 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive and neurodegenerative disorder of the cortex and hippocampus, which eventually leads to cognitive impairment. Although the etiology of AD remains unclear, the presence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.